Transcriptome-based prediction of drugs, inhibiting cardiomyogenesis in human induced pluripotent stem cells.
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
29 Aug 2023
29 Aug 2023
Historique:
received:
06
06
2023
accepted:
16
08
2023
revised:
31
07
2023
medline:
30
8
2023
pubmed:
30
8
2023
entrez:
29
8
2023
Statut:
epublish
Résumé
Animal studies for embryotoxicity evaluation of potential therapeutics and environmental factors are complex, costly, and time-consuming. Often, studies are not of human relevance because of species differences. In the present study, we recapitulated the process of cardiomyogenesis in human induced pluripotent stem cells (hiPSCs) by modulation of the Wnt signaling pathway to identify a key cardiomyogenesis gene signature that can be applied to identify compounds and/or stress factors compromising the cardiomyogenesis process. Among the 23 tested teratogens and 16 non-teratogens, we identified three retinoids including 13-cis-retinoic acid that completely block the process of cardiomyogenesis in hiPSCs. Moreover, we have identified an early gene signature consisting of 31 genes and associated biological processes that are severely affected by the retinoids. To predict the inhibitory potential of teratogens and non-teratogens in the process of cardiomyogenesis we established the "Developmental Cardiotoxicity Index" (CDI
Identifiants
pubmed: 37644023
doi: 10.1038/s41420-023-01616-6
pii: 10.1038/s41420-023-01616-6
pmc: PMC10465524
doi:
Types de publication
Journal Article
Langues
eng
Pagination
321Subventions
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : RTG 2624
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : RTG 2624
Informations de copyright
© 2023. Cell Death Differentiation Association (ADMC).
Références
Sachinidis A, Albrecht W, Nell P, Cherianidou A, Hewitt NJ, Edlund K, et al. Road map for development of stem cell-based alternative test methods. Trends Mol Med. 2019;25:470–81.
pubmed: 31130451
doi: 10.1016/j.molmed.2019.04.003
Acharya A, Nemade H, Papadopoulos S, Hescheler J, Neumaier F, Schneider T, et al. Microgravity-induced stress mechanisms in human stem cell-derived cardiomyocytes. iScience. 2022;25:104577.
pubmed: 35789849
pmcid: 9249673
doi: 10.1016/j.isci.2022.104577
Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today. 2015;105:140–56.
pubmed: 26043938
pmcid: 4737249
doi: 10.1002/bdrc.21096
Hengstler JG, Foth H, Kahl R, Kramer PJ, Lilienblum W, Schulz T, et al. The REACH concept and its impact on toxicological sciences. Toxicology. 2006;220:232–9.
pubmed: 16555380
doi: 10.1016/j.tox.2005.12.005
Leist M, Ringwald A, Kolde R, Bremer S, van Thriel C, Krause KH, et al. Test systems of developmental toxicity: state-of-the art and future perspectives. Arch Toxicol. 2013;87:2037–42.
pubmed: 24190503
doi: 10.1007/s00204-013-1154-x
Adler S, Basketter D, Creton S, Pelkonen O, van Benthem J, Zuang V, et al. Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. Arch Toxicol. 2011;85:367–485.
pubmed: 21533817
doi: 10.1007/s00204-011-0693-2
Hartung T, Daston G. Are in vitro tests suitable for regulatory use? Toxicol Sci. 2009;111:233–7.
pubmed: 19617452
doi: 10.1093/toxsci/kfp149
Shukla SJ, Huang R, Austin CP, Xia M. The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform. Drug Discov Today. 2010;15:997–1007.
pubmed: 20708096
pmcid: 2994991
doi: 10.1016/j.drudis.2010.07.007
Brown ES, Jacobs A, Fitzpatrick S. Reproductive and developmental toxicity testing: from in vivo to in vitro. Altex. 2012;29:333–9.
pubmed: 23019687
Krug AK, Kolde R, Gaspar JA, Rempel E, Balmer NV, Meganathan K, et al. Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013;87:123–43.
pubmed: 23179753
doi: 10.1007/s00204-012-0967-3
Meganathan K, Jagtap S, Wagh V, Winkler J, Gaspar JA, Hildebrand D, et al. Identification of thalidomide-specific transcriptomics and proteomics signatures during differentiation of human embryonic stem cells. PLoS One. 2012;7:e44228.
pubmed: 22952932
pmcid: 3429450
doi: 10.1371/journal.pone.0044228
Shinde V, Chaudhari U, Sotiriadou I, Hescheler J, Sachinidis A. In vitro methods for cardiotoxicity testing. In: Bal-Price A, Jennings P editors. In vitro toxicology systems. New York: Springer; 2014, pp 45–77.
Shinde V, Klima S, Sureshkumar PS, Meganathan K, Jagtap S, Rempel E, et al. Human pluripotent stem cell based developmental toxicity assays for chemical safety screening and systems biology data generation. J Vis Exp. 2015;100:e52333.
Shinde V, Sureshkumar P, Sotiriadou I, Hescheler J, Sachinidis A. Human embryonic and induced pluripotent stem cell based toxicity testing models: future applications in new drug discovery. Curr Med Chem. 2016;23:3495–509.
pubmed: 27356535
doi: 10.2174/0929867323666160627113436
Shinde V, Perumal Srinivasan S, Henry M, Rotshteyn T, Hescheler J, Rahnenfuhrer J, et al. Comparison of a teratogenic transcriptome-based predictive test based on human embryonic versus inducible pluripotent stem cells. Stem Cell Res Ther. 2016;7:190.
pubmed: 28038682
pmcid: 5203708
doi: 10.1186/s13287-016-0449-2
Meigs L, Smirnova L, Rovida C, Leist M, Hartung T. Animal testing and its alternatives - the most important omics is economics. Altex. 2018;35:275–305.
pubmed: 30008008
doi: 10.14573/altex.1807041
Shinde V, Hoelting L, Srinivasan SP, Meisig J, Meganathan K, Jagtap S, et al. Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017;91:839–64.
pubmed: 27188386
doi: 10.1007/s00204-016-1741-8
Jaklin M, Zhang JD, Schäfer N, Clemann N, Barrow P, Küng E, et al. Optimization of the TeraTox assay for preclinical teratogenicity assessment. Toxicol Sci. 2022;188:17–33.
pubmed: 35485993
pmcid: 9237991
doi: 10.1093/toxsci/kfac046
Balmer NV, Weng MK, Zimmer B, Ivanova VN, Chambers SM, Nikolaeva E, et al. Epigenetic changes and disturbed neural development in a human embryonic stem cell-based model relating to the fetal valproate syndrome. Hum Mol Genet. 2012;21:4104–14.
pubmed: 22723015
doi: 10.1093/hmg/dds239
Dreser N, Madjar K, Holzer AK, Kapitza M, Scholz C, Kranaster P, et al. Development of a neural rosette formation assay (RoFA) to identify neurodevelopmental toxicants and to characterize their transcriptome disturbances. Arch Toxicol. 2020;94:151–71.
pubmed: 31712839
doi: 10.1007/s00204-019-02612-5
Meisig J, Dreser N, Kapitza M, Henry M, Rotshteyn T, Rahnenführer J, et al. Kinetic modeling of stem cell transcriptome dynamics to identify regulatory modules of normal and disturbed neuroectodermal differentiation. Nucleic Acids Res. 2020;48:12577–92.
pubmed: 33245762
pmcid: 7736781
doi: 10.1093/nar/gkaa1089
Meganathan K, Jagtap S, Srinivasan SP, Wagh V, Hescheler J, Hengstler J, et al. Neuronal developmental gene and miRNA signatures induced by histone deacetylase inhibitors in human embryonic stem cells. Cell Death Dis. 2015;6:e1756.
pubmed: 25950486
pmcid: 4669700
doi: 10.1038/cddis.2015.121
Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci USA. 2012;109:E1848–57.
pubmed: 22645348
pmcid: 3390875
doi: 10.1073/pnas.1200250109
Cherianidou A, Seidel F, Kappenberg F, Dreser N, Blum J, Waldmann T, et al. Classification of developmental toxicants in a human iPSC transcriptomics-based test. Chem Res Toxicol. 2022;35:760–73.
pubmed: 35416653
pmcid: 9377669
doi: 10.1021/acs.chemrestox.1c00392
Seidel F, Cherianidou A, Kappenberg F, Marta M, Dreser N, Blum J, et al. High accuracy classification of developmental toxicants by in vitro tests of human neuroepithelial and cardiomyoblast differentiation. Cells. 2022;11:3404.
Tosic J, Kim G-J, Pavlovic M, Schröder CM, Mersiowsky S-L, Barg M, et al. Eomes and Brachyury control pluripotency exit and germ-layer segregation by changing the chromatin state. Nat Cell Biol. 2019;21:1518–31.
pubmed: 31792383
doi: 10.1038/s41556-019-0423-1
Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.
pubmed: 30944313
pmcid: 6447622
doi: 10.1038/s41467-019-09234-6
Acharya A, Nemade H, Rajendra Prasad K, Khan K, Hescheler J, Blackburn N, et al. Live-cell imaging of the contractile velocity and transient intracellular Ca(2+) fluctuations in human stem cell-derived cardiomyocytes. Cells. 2022;11:1280.
Vargesson N. The teratogenic effects of thalidomide on limbs. J Hand Surg Eur Vol. 2019;44:88–95.
pubmed: 30335598
doi: 10.1177/1753193418805249
Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol. 2009;28:1–10.
pubmed: 19490988
doi: 10.1016/j.reprotox.2009.02.014
Ornoy A, Weinstein-Fudim L, Becker M. SAMe, choline, and valproic acid as possible epigenetic drugs: their effects in pregnancy with a special emphasis on animal studies. Pharmaceuticals. 2022;15:192.
pubmed: 35215304
pmcid: 8879727
doi: 10.3390/ph15020192
Keegan BR, Feldman JL, Begemann G, Ingham PW, Yelon D. Retinoic acid signaling restricts the cardiac progenitor pool. Science. 2005;307:247–9.
pubmed: 15653502
doi: 10.1126/science.1101573
Ueno S, Weidinger G, Osugi T, Kohn AD, Golob JL, Pabon L, et al. Biphasic role for Wnt/beta-catenin signaling in cardiac specification in zebrafish and embryonic stem cells. Proc Natl Acad Sci USA. 2007;104:9685–90.
pubmed: 17522258
pmcid: 1876428
doi: 10.1073/pnas.0702859104
Tam PP, Loebel DA. Gene function in mouse embryogenesis: get set for gastrulation. Nat Rev Genet. 2007;8:368–81.
pubmed: 17387317
doi: 10.1038/nrg2084
Engberg N, Kahn M, Petersen DR, Hansson M, Serup P. Retinoic acid synthesis promotes development of neural progenitors from mouse embryonic stem cells by suppressing endogenous, Wnt-dependent nodal signaling. Stem Cells. 2010;28:1498–509.
pubmed: 20665854
doi: 10.1002/stem.479
Ruiz-Villalba A, Hoppler S, van den Hoff MJB. Wnt signaling in the heart fields: variations on a common theme. Dev Dyn. 2016;245:294–306.
pubmed: 26638115
doi: 10.1002/dvdy.24372
Wiesinger A, Boink GJJ, Christoffels VM, Devalla HD. Retinoic acid signaling in heart development: application in the differentiation of cardiovascular lineages from human pluripotent stem cells. Stem. Cell Rep. 2021;16:2589–606.
doi: 10.1016/j.stemcr.2021.09.010
Perl E, Waxman JS. Reiterative mechanisms of retinoic acid signaling during vertebrate heart development. J Dev Biol. 2019;7:11.
Bernheim S, Meilhac SM. Mesoderm patterning by a dynamic gradient of retinoic acid signalling. Philos Trans R Soc Lond B Biol Sci. 2020;375:20190556.
pubmed: 32829679
pmcid: 7482219
doi: 10.1098/rstb.2019.0556
Schuldiner M, Eiges R, Eden A, Yanuka O, Itskovitz-Eldor J, Goldstein RS, et al. Induced neuronal differentiation of human embryonic stem cells. Brain Res. 2001;913:201–5.
pubmed: 11549388
doi: 10.1016/S0006-8993(01)02776-7
Kim DS, Lee JS, Leem JW, Huh YJ, Kim JY, Kim HS, et al. Robust enhancement of neural differentiation from human ES and iPS cells regardless of their innate difference in differentiation propensity. Stem Cell Rev Rep. 2010;6:270–81.
pubmed: 20376579
doi: 10.1007/s12015-010-9138-1
Okada Y, Shimazaki T, Sobue G, Okano H. Retinoic-acid-concentration-dependent acquisition of neural cell identity during in vitro differentiation of mouse embryonic stem cells. Dev Biol. 2004;275:124–42.
pubmed: 15464577
doi: 10.1016/j.ydbio.2004.07.038
Pearce JJ, Evans MJ. Mml, a mouse Mix-like gene expressed in the primitive streak. Mech Dev. 1999;87:189–92.
pubmed: 10495285
doi: 10.1016/S0925-4773(99)00135-5
Inman KE, Downs KM. Localization of Brachyury (T) in embryonic and extraembryonic tissues during mouse gastrulation. Gene Expr Patterns. 2006;6:783–93.
pubmed: 16545989
doi: 10.1016/j.modgep.2006.01.010
Clément S, Stouffs M, Bettiol E, Kampf S, Krause KH, Chaponnier C, et al. Expression and function of alpha-smooth muscle actin during embryonic-stem-cell-derived cardiomyocyte differentiation. J Cell Sci. 2007;120:229–38.
pubmed: 17179203
doi: 10.1242/jcs.03340
Waxman JS, Yelon D. Increased Hox activity mimics the teratogenic effects of excess retinoic acid signaling. Dev Dyn. 2009;238:1207–13.
pubmed: 19384962
pmcid: 2739864
doi: 10.1002/dvdy.21951
Deng X, Zhou J, Li FF, Yan P, Zhao EY, Hao L, et al. Characterization of nodal/TGF-lefty signaling pathway gene variants for possible roles in congenital heart diseases. PLoS One. 2014;9:e104535.
pubmed: 25111179
pmcid: 4128709
doi: 10.1371/journal.pone.0104535
Meno C, Shimono A, Saijoh Y, Yashiro K, Mochida K, Ohishi S, et al. lefty-1 Is Required for Left-Right Determination as a Regulator of lefty-2 and nodal. Cell. 1998;94:287–97.
pubmed: 9708731
doi: 10.1016/S0092-8674(00)81472-5
Oulad-Abdelghani M, Chazaud C, Bouillet P, Mattei MG, Dollé P, Chambon P. Stra3/lefty, a retinoic acid-inducible novel member of the transforming growth factor-beta superfamily. Int J Dev Biol. 1998;42:23–32.
pubmed: 9496783
Schier AF, Shen MM. Nodal signalling in vertebrate development. Nature. 2000;403:385–9.
pubmed: 10667782
doi: 10.1038/35000126
Kumar P, Kumar HA, Sundaresan L, Ghosh A, Kathirvel P, Thilak A, et al. Thalidomide remodels developing heart in chick embryo: discovery of a thalidomide mediated hematoma in heart muscle. Naunyn Schmiedebergs Arch Pharmacol. 2018;391:1093–105.
pubmed: 29982937
doi: 10.1007/s00210-018-1532-2
Wu G, Nan C, Rollo JC, Huang X, Tian J. Sodium valproate-induced congenital cardiac abnormalities in mice are associated with the inhibition of histone deacetylase. J Biomed Sci. 2010;17:16.
pubmed: 20219112
pmcid: 2841099
doi: 10.1186/1423-0127-17-16
Fahdi IE, Gaddam V, Saucedo JF, Kishan CV, Vyas K, Deneke MG, et al. Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol. 2004;93:1052–5.
pubmed: 15081457
doi: 10.1016/j.amjcard.2003.12.061
Moudgil R, Yeh ETH. Mechanisms of cardiotoxicity of cancer chemotherapeutic agents: cardiomyopathy and beyond. Can J Cardiol. 2016;32:863–70.e5.
pubmed: 27117975
doi: 10.1016/j.cjca.2016.01.027
Meyer T, Maier A, Borisow N, Dullinger JS, Splettstösser G, Ohlraun S, et al. Thalidomide causes sinus bradycardia in ALS. J Neurol. 2008;255:587–91.
pubmed: 18425621
doi: 10.1007/s00415-008-0756-3
Genschow E, Scholz G, Brown N, Piersma A, Brady M, Clemann N, et al. Development of prediction models for three in vitro embryotoxicity tests in an ECVAM validation study. Vitr Mol Toxicol. 2000;13:51–66.
Chaudhari U, Nemade H, Wagh V, Gaspar JA, Ellis JK, Srinivasan SP, et al. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment. Arch Toxicol. 2016;90:2763–77.
pubmed: 26537877
doi: 10.1007/s00204-015-1623-5